Navigation Links
Genetics Should Decide Warfarin Dose, Study Reiterates
Date:3/20/2009

What works for some people might be dangerous for others,,

FRIDAY, March 20 (HealthDay News) -- Researchers have confirmed previously reported genetic factors that may help doctors more accurately prescribe the proper dosage of the blood thinner warfarin to people at high risk of cardiovascular problems.

According to U.S. Food and Drug Administration estimates, about 2 million Americans use the anticoagulant medication to prevent blood clots and reduce the likelihood of a stroke, pulmonary embolism or heart attack.

Though the drug can be very effective, the optimal therapeutic dosage varies as much as 20-fold among individuals, with too high a dose risking severe bleeding and too small a dose failing to protect against the original cardiovascular worry. Trial and error followed by frequent monitoring of blood levels have been the common method of determining the proper dose for a given person.

Researchers from Sweden and the United Kingdom, studying the genetic makeup of more than 1,000 warfarin users, reported finding three genes -- VKORC1, CYP2C9 and CYP4F2 -- with common variants that explain more than 40 percent of the variability in optimal dosing levels. VKORC1, which affects the liver's ability to use and excrete warfarin, and CYP2C9, which helps with the essential blot-clotting vitamin K, were found to be responsible for the vast majority of the variability, according to the study. The findings were to be published March 20 in PLoS Genetics.

The finding appears to support a study in the Feb. 19 issue of the New England Journal of Medicine. In that report, American researchers collected data -- including the VKORC1 and CYP2C9 variants -- from more than 4,000 people taking warfarin and created an algorithm that had a high rate of success predicting the ideal dose of the drug.

More information

The U.S. National Library of Medicine has more about warfarin.



-- Kevin McKeever



SOURCES: PLoS Genetics, news release, March 19, 2009; New England Journal of Medicine, Feb. 19, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Genetics Hold Promise, Challenges for Cancer Care
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Salugen to Present Research on Generational Associations of Reward Deficiency Syndrome at XVth World Congress on Psychiatric Genetics
4. Obesity genetics
5. The genetics of MLL leukemogenesis
6. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
7. Clarient Names Michele Hibbard, Ph.D. Director of Genetics
8. Response Genetics Announces Presentation/Webcast at BIOCOM Investor Conference
9. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
10. Response Genetics to Announce Third Quarter 2007 Financial Results on Wednesday, November 14, 2007
11. Response Genetics Reports Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Genetics Should Decide Warfarin Dose, Study Reiterates
(Date:2/23/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Beach to host its Swirl: Miami Wine Tasting Event on March 28, 2017. ...
(Date:2/23/2017)... CA (PRWEB) , ... February 23, 2017 , ... Los ... two episodes of WE TV’s “Mama June: From Not to Hot,” which will begin ... notable, “Mama” June Shannon, known to millions from the 2012 reality television series, “Here ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... exciting, new, interactive publication where generations converge and explore the world from different ... worldview, Dialog Magazine enables readers to gain understanding, increase empathy, and find greater ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & ... in the fight against cancer, has produced a seminal study that asked cancer ... release top-line findings in a webinar, Defining Compassionate Care Through the Voices of ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 2017  Genesis Healthcare Services has merged with Hospice ... by Bill Monast , President and CEO of ... Nathan Feltman , executives with Home Health Depot, Inc., ... This acquisition helps Hospice Cloud maintain its ... durable medical equipment (DME) solutions for the hospice industry. ...
(Date:2/23/2017)... Research and Markets has announced the addition of the ... offering. ... Menopause Drugs Price Analysis and Strategies - 2016, provides drug pricing data ... following questions: What are the key drugs ... the Global Menopause market? What are the unit prices ...
(Date:2/23/2017)... , Feb. 23, 2017 Regulus ... the discovery and development of innovative medicines targeting microRNAs, ... year 2016 financial results on Thursday, March 2, 2017 ... a conference call and webcast on March 2, 2017 ... and full year 2016 financial results and provide a ...
Breaking Medicine Technology: